152 related articles for article (PubMed ID: 18395138)
41. Agalsidase beta (Fabrazyme) for Fabry disease.
Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
[No Abstract] [Full Text] [Related]
42. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease.
Dehout F; Roland D; Treille de Granseigne S; Guillaume B; Van Maldergem L
J Inherit Metab Dis; 2004; 27(4):499-505. PubMed ID: 15303007
[TBL] [Abstract][Full Text] [Related]
43. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
[TBL] [Abstract][Full Text] [Related]
44. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
Banikazemi M; Desnick RJ
Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
[No Abstract] [Full Text] [Related]
45. [Intravenous lidocaine as treatment for the painful episodes in Fabry's disease].
Politei JM
Rev Neurol; 2009 Aug 1-15; 49(3):166-7. PubMed ID: 19621314
[No Abstract] [Full Text] [Related]
46. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
Hollak CE; Linthorst GE
Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
[No Abstract] [Full Text] [Related]
47. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.
Ramaswami U; Whybra C; Parini R; Pintos-Morell G; Mehta A; Sunder-Plassmann G; Widmer U; Beck M;
Acta Paediatr; 2006 Jan; 95(1):86-92. PubMed ID: 16498740
[TBL] [Abstract][Full Text] [Related]
48. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
49. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Wendt S; Whybra C; Kampmann C; Teichmann E; Beck M
J Inherit Metab Dis; 2005; 28(5):787-8. PubMed ID: 16151910
[TBL] [Abstract][Full Text] [Related]
50. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis and management of kidney involvement in Fabry disease.
Warnock DG; West ML
Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
[TBL] [Abstract][Full Text] [Related]
52. Images in cardiovascular medicine. Myocardial fibrosis in fabry disease demonstrated by multislice computed tomography: comparison with biopsy findings.
Funabashi N; Toyozaki T; Matsumoto Y; Yonezawa M; Yanagawa N; Yoshida K; Komuro I
Circulation; 2003 May; 107(19):2519-20. PubMed ID: 12756193
[No Abstract] [Full Text] [Related]
53. First treatment for Fabry's disease.
FDA Consum; 2003; 37(4):4. PubMed ID: 12971327
[No Abstract] [Full Text] [Related]
54. Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease.
Lien YH; Lai LW
Am J Orthop (Belle Mead NJ); 2005 Apr; 34(4):192-4. PubMed ID: 15913175
[TBL] [Abstract][Full Text] [Related]
55. Anderson-Fabry disease in children.
Sestito S; Ceravolo F; Concolino D
Curr Pharm Des; 2013; 19(33):6037-45. PubMed ID: 23448455
[TBL] [Abstract][Full Text] [Related]
56. Reversal of first-degree atrioventricular block in Fabry disease.
Blum A; Podovitzky O; Sheiman J; Khasin M
Arch Intern Med; 2009 Nov; 169(20):1925-6. PubMed ID: 19901148
[No Abstract] [Full Text] [Related]
57. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
Basic-Jukic N; Kes P; Mokos I; Coric M
Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
[No Abstract] [Full Text] [Related]
58. Novel α-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease.
Wakakuri H; Nakamura S; Utsumi K; Shimizu W; Yasutake M
Int Heart J; 2016 Sep; 57(5):637-9. PubMed ID: 27593536
[TBL] [Abstract][Full Text] [Related]
59. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
Germain DP
Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
[No Abstract] [Full Text] [Related]
60. Clinical trial for Fabry disease faces continuing hurdles.
Silversides A
CMAJ; 2009 Nov; 181(11):E251-2. PubMed ID: 19825933
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
